Master Summary

Cross-pillar synthesis with actionable recommendations for AU/NZ entry.

The GLP-1 companion supplement opportunity in AU/NZ is real, quantified, and uncontested — but it is a 12–18 month window, not a permanent whitespace. Australia has 490,000–500,000 active GLP-1 users spending up to AUD $5,000/year on medication with no PBS subsidy for obesity; New Zealand has ~62,000 Wegovy users, all private-pay, since July 2025.^[8] Clinical research confirms 98.6% of GLP-1 patients fall below the vitamin D DRI, 89.9% below magnesium, and 39–45.5% of their total weight loss is lean muscle — yet no dedicated GLP-1 companion supplement brand operates in either market today. The launch window is open. The evidence base is sufficient. The competitive clock is running.

Research Overview

The evidence supporting this thesis spans regulatory filings, peer-reviewed clinical literature, official PBS and Pharmac prescription data, public company disclosures, and primary consumer research — but the confidence levels are not uniform, and the difference matters for how each finding should be used. The clinical case is the strongest: peer-reviewed RCTs and a 461,382-patient retrospective cohort underwrite the deficiency and lean-mass claims. AU/NZ market sizing is moderate-confidence — official prescription volumes are exact, but the supplement attach rate uses US proxies because no AU/NZ-specific study exists. Channel economics is the weakest surface: no AU/NZ DTC has ever publicly disclosed actual CAC, so every figure here is triangulated from US comparables and platform-level data. Where this report is most likely to be wrong, it is wrong about CAC — every model should stress-test at 1.5–2× the central estimate.

Three structural facts define the opportunity:

1. The private-pay window is open. Both funding bodies moved in late 2025 — PBAC positive in November, Pharmac's advisory group at high priority in December — but as of mid-2026, 100% of weight-loss GLP-1 prescriptions in both countries remain out-of-pocket. This is not a failure condition; it is the commercial sweet spot. Self-funding patients are the highest-willingness-to-pay cohort, and funding arrival will massively expand user volume while compressing per-patient supplement spend. The DTC brand that establishes clinical credibility and GP/pharmacist relationships during the private-pay era is structurally positioned for the volume wave that follows.
2. No AU/NZ incumbent has claimed the position. Confirmed after systematic review of Blackmores, Swisse, Healtheries, Go Healthy, BePure, Two Islands, Hardy's, and all five AU/NZ telehealth platforms. The only confirmed NZ-facing competitor is Naturecan NZ — a UK-origin brand with a NZ-facing online store and no local clinical credibility.
3. The US market — 18–36 months ahead — defines the category trajectory. GLP-1 supplement searches grew 792% YoY in 2024, the category has a 124% CAGR in product claims launches, and established brands now sell at USD $65–$105/month, with observed premiums of 25–45% over conventional products and 80% of GLP-1 users willing to pay a premium for targeted formulations.^[2][5]

Major Findings

1. The Demand Signal: Documented, Clinically Quantified, and Unmet

The single most important convergence across this research is that the clinical case and the behavioral case tell the same story independently. Clinical evidence: a large retrospective cohort of 461,382 adults newly prescribed GLP-1 agonists found 22.4% developed a diagnosed nutritional deficiency within 12 months — vitamin D deficiency at 13.6%, iron deficiency anemia doubling from 1.6% to 3.2%.^[1] A 2025 cross-sectional dietary intake study (Frontiers in Nutrition, n=69) found 98.6% below the vitamin D DRI, 89.9% below magnesium, 88.4% below iron — not marginal shortfalls, structural deficits.^[1] A February 2026 meta-analysis of six studies (N=480,825) confirmed vitamin D as the most prevalent deficiency and prompted Harvard Health to recommend daily multivitamin supplementation as standard of care.^[1]

Behavioral evidence: 85% of GLP-1 users who experience side effects actively purchase products to manage symptoms or address nutrition gaps, with roughly one-third each buying protein shakes, protein powders, and protein bars.^[2] GLP-1 households outspend matched non-GLP-1 households by +22% on protein-enriched products, +38% on fresh vegetables, while cutting traditional snack spending by 31% (NielsenIQ panel).^[2] Supplement spend among tracked GLP-1 users increased +58% on superfoods, +38% on protein shakes, and +23% on bone health products year-over-year (Numerator, n=30,000).^[2] The gap is not a hypothesis waiting for proof — it is happening, measurably, right now.

The most actionable number in this dataset: only 20% of GLP-1 users are referred to a registered dietitian, and 60% report inadequate nutritional guidance from their prescribing provider. The supplement market is not filling a discretionary want. It is filling a clinical void left by standard prescribing practice. That is a defensible market position that incumbents without clinical credibility cannot replicate with distribution alone.

The GI side-effect dimension adds a second layer of demand. Pooled STEP data shows semaglutide 2.4 mg produced nausea in 43.9% of patients, vomiting in 24.5%, and constipation in 24.2%.^[1] The clinical problem is not the acute events themselves (99.5% are non-serious) but the dietary modifications used to manage them: patients told to avoid high-fiber foods, legumes, and dairy systematically deepen the deficiencies that supplementation addresses. GI symptom management and nutritional supplementation are not parallel products — they are the same intervention.^[1][2]

2. Lean Mass Loss: The Headline Claim, With Important Drug-Specific Nuance

Semaglutide users lose 6.92 kg of lean muscle on average — 39 to 45.5% of their total weight loss is muscle, not fat. That figure comes from the STEP 1 DXA substudy (n=140, 68 weeks), the most-cited evidence for the muscle-loss thesis.^[1] The SURMOUNT-1 DXA substudy (n=160, 72 weeks) tells a more favorable story for tirzepatide: approximately 74% fat mass, 26% lean mass of the 21.3% total weight lost.^[1] A contested non-peer-reviewed preprint claims tirzepatide produced greater lean mass loss than semaglutide at each time point, with a "Depletive GLP-1 metabotype" in 10.3% vs. 6.7% of patients — this directly conflicts with SURMOUNT-1 trial data and should not be cited in marketing or investor materials as established.^[1]

The practical read: lean mass loss is real, drug-dependent, and most severe in older adults with T2D — the population most commonly prescribed. A 24-month retrospective cohort of 220 older semaglutide users documented accelerated appendicular skeletal muscle mass decline of 0.39 kg/m² in women and 0.26 kg/m² in men, both significantly exceeding matched controls, with 27.7% already sarcopenic at baseline.^[1] For a supplement product positioned on muscle preservation, the Muscle Protect thesis is clinically defensible — with the caveat that efficacy claims must reference protein intake adequacy, not drug interaction, and should use language anchored to the 1.2–1.6 g/kg/day threshold rather than comparisons to untreated groups.

3. Market Size: Two Very Different Bets

The globally-circulated US$4.2B (2025) → US$8.4B (2030) market size figure has no confirmed primary source. The closest verifiable anchor is Future Market Insights, which publishes USD $4.1B (2025) → USD $13.0B (2035) at 12.2% CAGR — a materially different trajectory. Projecting the FMI base at their own stated CAGR yields ~$7.3B by 2030, not $8.4B; reaching $8.4B by 2030 requires a ~15% CAGR that FMI does not claim. The figure is Tier-4 credibility (ESOMAR certified but via syndicated press releases with no published methodology) and provides no country-level AU/NZ disaggregation. Use it only as global category color, not as the basis for TAM calculations in investor decks.^[3]

The bottom-up AU/NZ model, built from PBS/Pharmac prescription volumes × attach rate × ARPU, produces investor-grade numbers:

The model assumptions: 25–30% attach rate (US Acosta survey proxy, conservative for early AU/NZ market); AUD $100–$150/month ARPU for a protein + micronutrient + GI bundle. No AU/NZ-specific attach rate data exists — this is the primary input uncertainty. The private-pay sub-segment is the highest-value SAM: 180,000–240,000 Australians paying AUD $4,000–$5,000/year on medication alone carry 3–4× higher willingness to pay for companion supplements than future PBS patients subsidized at ~AUD $25/script.^[3][4] An entry strategy targeting the private-pay cohort exclusively can build to AUD $10–$20M revenue before PBS listing creates the larger but lower-ARPU mass market.^[3]

4. Competitive Landscape: Open Today, Closing Within 18 Months

Zero AU/NZ-native GLP-1 companion supplement brand exists in May 2026. Not "few." Not "mostly whitespace." Zero — confirmed across Blackmores, Swisse, Healtheries, Go Healthy, BePure, Two Islands, Hardy's, and every AU/NZ telehealth platform reviewed. The systematic competitive map:

The competitive map above is drawn from systematic May 2026 brand review across the Competitive Landscape and Strategic Risk pillars.^[5][7] The US category — 18–36 months ahead — defines the ceiling. Core DTC sweet spot is USD $60–$105/month, subscription discounts of 10–60% are universal, and protein is present in 7 of 8 major brands reviewed. The most differentiated entrant, Pendulum GLP-1 Probiotic, holds an FDA Breakthrough Designation for its Glucose Control product and reported 91% cravings reduction in a 274-participant consumer study at USD $65–$95/month.^[5] The US market is now crossing into specialty retail: The Vitamin Shoppe launched a dietitian-formulated private-label GLP-1 line across 750+ stores in March 2025. This is the two-to-three year trajectory for AU/NZ if the category proves commercially viable — providing both the urgency and the blueprint.

The Hims & Hers acquisition of Eucalyptus for USD $1.15 billion is the single most credible medium-term threat. Hims & Hers already cross-sells companion supplements on its US platform; Eucalyptus has AU telehealth infrastructure and Juniper has UK presence. NZ expansion is not confirmed, but the capability is assembled. The question is not whether this operator enters — it is whether a NZ-native brand has established clinical credibility and GP/pharmacist relationships before it does.^[4][5]

5. Consumer Behavior: High Intent, Price-Sensitive in Context

Eight out of ten GLP-1 users are willing to pay a premium for products formulated specifically for them — and they already do, at observed premiums of 25–45% above conventional supplements. 80% report willingness-to-pay; 83% explicitly say they want customized solutions (ADM consumer research).^[2] Active users already spend $95–$130/month on specialized GLP-1-compatible products in the US.^[2] The three most-demanded product attributes — cited by 73–75% of shoppers — are vitamin/nutrient fortification, high protein, and gut health support. These three attributes in one SKU is an architecture that only ~1% of global products currently satisfy.^[2][5]

AU/NZ pricing must be calibrated to drug cost burden. A patient paying NZD $475/month for Wegovy at maintenance is spending NZD $5,700/year before supplements. 74% of Australians cite rising living costs as a major concern even among those self-funding GLP-1 drugs.^[2] The US willingness-to-pay ceiling ($95–$130/month) does not translate directly; a mid-premium position of AUD/NZD $80–$120/month with a clear value-per-dollar narrative is more appropriate than matching US premium pricing.

The psychographic profile is commercially favorable: Morning Consult data (n=58,008) shows weight-loss GLP-1 users skew Gen X (35%) and Millennial (31%), urban (41%), affluent (31% earn $100K+), and early adopters (+15pp). They over-index on TikTok by +32pp, Reddit by +22pp, Instagram by +21pp, and 40% use social media as their primary health information source. 80% research products actively before purchase; only 37% consult a medical professional — DTC content is the primary discovery channel, not clinical referral.^[2]

The post-discontinuation cohort is too large to ignore. 75–90% of GLP-1 users eventually discontinue; Australian clinical records (MJA, n=1,911) show only 19% persistence at 12 months.^[2] After stopping, patients regain weight at 0.4 kg/month — 4× faster than diet or exercise approaches — with a higher fat-to-muscle ratio than pre-treatment. Critically, 76% of discontinuers maintain the same or lower food intake after stopping, and 46% say they would restart if costs decreased.^[2] A pause-to-resume subscription flow targeting this cohort is a free retention lever that most subscription brands do not build for.

6. Acquisition Economics: Viable Only With the Right Architecture

No AU/NZ DTC health company has ever disclosed actual CAC or LTV figures publicly. The best benchmarks are inferential: Hims & Hers public unit economics imply alternative-methodology CAC of ~USD $89 against ~USD $338 LTV with payback under 9 months; standard methodology (disclosed marketing spend ÷ net new subscribers) produces materially higher CAC figures, so the $89 anchor should be used as a directional floor rather than a point estimate.^[4] At AUD ~$150 blended CAC and 72%+ gross margins, reaching 3:1 LTV:CAC floor requires retaining subscribers for 9–10 months at AUD $50/month AOV; the 4:1 target requires either 50%+ retention or a price point above $70/month.^[4]

Channel costs on Meta and Google Health & Wellness inventory continued rising through 2025 while ROAS compressed — a multi-year-high pattern. TikTok remains the cost outlier: platform-level CPMs fell materially YoY into 2026, and TikTok Shop CPA runs 30–50% below traditional TikTok formats. The structural catch: ad spend is only 50–60% of total TikTok CAC once content production and creator fees are included, and attribution requires multi-touch modeling as conversion typically happens days later via branded search.^[4] The practical channel architecture: TikTok nano-influencer portfolio (18% engagement vs 1.42% on Instagram for mega-influencers) for discovery; podcast advertising for intent-level conversion (70% of health podcast listeners made a purchase after hearing a supplement sponsorship); GP/pharmacist referral as the trust anchor that DTC-only brands cannot replicate.^[4][2]

Retention is the business model. Annual plans reduce churn by 51% versus monthly billing^[2] — this should be the default acquisition offer, not an upsell. Prepaid 3–6 month plans increase retention by 40%. Involuntary churn from failed payments accounts for 22% of total supplement brand churn and is recoverable via dunning automation (Recharge + Klaviyo combination recovers +14% of involuntary churners).^[4] The first 30 days post-acquisition is the single largest predictor of 12-month retention; educational email sequences targeting the 15–45 day window are the primary documented driver of the difference between the 40% industry average and 55%+ top-performer retention.^[4]

7. Regulatory: The Claims Language is a Legal Instrument, Not Boilerplate

In every market Nouri will enter — NZ, AU, UK, Canada, and GCC — the words on the label aren't marketing. They're the regulatory pathway. Say "supports metabolic health" and you're selling a supplement; say "boosts GLP-1 production" and you've committed an unauthorized health claim — a criminal offence in the UK since 1 October 2024. Medsafe holds that any claim implying, alluding to, or suggesting a therapeutic purpose converts a supplement into a medicine under Section 4 of the Medicines Act 1981. The TGA states explicitly: "a change in wording on a label can alter the entire regulatory pathway." The MHRA tie-break rule: a product qualifying as both food and medicinal product is classified as the medicinal product. The UK ASA in August 2025 banned not just named drug references but "like GLP-1 drugs just natural," "boosts GLP-1 production," and even "support metabolism" as GLP-1-adjacent — via an AI monitoring system that proactively scans, not just responds to complaints.^[6]

The permissible language framework across markets converges on: "supports healthy weight management," "supports metabolic health," "supports digestive comfort," "supports muscle health during caloric restriction." The prohibited zone includes all drug-comparison language, mechanism references (GLP-1 stimulation, metabolism modification), pharmaceutical equivalence claims, and any language that appears in influencer briefs or UGC — the enforcement perimeter extends to the full consumer-facing stack.^[6]

Market entry sequencing by regulatory gate:

• NZ: No pre-market registration required; claims review before launch is sufficient. Fastest entry. Maximum fine for violations: NZD $500,000 per breach (raised from NZ$500 under the Food Act 2014).^[6][5]
• AU: ARTG listing (AUST L) required before supply; GMP compliance documentation required; 778 permissible indications available via self-certification. 4–8 week process for straightforward formulations.^[6]
• UK: No product registration required, but unauthorized nutrition/health claims are a criminal offence since 1 October 2024. MHRA borderline classification opinion (covers up to 4 products per inquiry) is effectively mandatory before any weight-management product goes live.^[6]
• Canada: Natural Product Number (NPN) product licence mandatory before supply. 180-day Health Canada review target implies 12–18 month lead time. Start immediately for any Canadian launch plan. ~3 million Canadian GLP-1 users with generic semaglutide (first G7 country to approve) expected to reduce costs 65% — substantial expansion opportunity.^[6]
• GCC: Halal certification is a hard prerequisite for any animal-derived ingredient (gelatin capsules trigger this). UAE bilingual labelling (English + Arabic) is a market entry condition. Saudi SFDA is the strictest GCC regulator; updated guidance Q1–Q2 2024.^[6]

8. Defensibility: Data and Provenance Are the Durable Moats

Product-level moats in supplements are structurally weak: white-label formulas can be replicated in 3–6 months, private-label manufacturers can supply competitors, and a well-resourced entrant can undercut on price within 9–15 months using existing manufacturing scale.^[7] The IP hierarchy runs from no defensibility (white label) through moderate-only (private label, where the manufacturer retains the formula) to fortress-level (custom formulation with full IP ownership transfer + patents + trademarks + brand trust + retailer relationships). Startups with patents are 10× more likely to secure funding. Patent prosecution on a novel GLP-1 companion nutrition formulation combination should be initiated within months 1–12 — not 12–24.^[7]

NZ-manufactured provenance is the one moat that AU incumbents structurally cannot replicate. New Zealand's natural health products sector generates $652.3M in export sales; over 40 million people globally consume NZ food products. Blackmores manufactures offshore; Swisse is China-owned (H&H Group) with no NZ manufacturing claim. FernMark certification provides verifiable QR-code provenance, with growing recognition in China and Southeast Asia where premium food provenance commands material price premiums.^[7] This matters most as an export story: NZ manufacturing + FernMark enables multi-market certifications (TGA + FDA + CNCA + Halal) from a single facility and positions AU/UK/GCC expansion as extensions of a premium provenance story, not an AU or US brand entering NZ.

The subscriber data feedback loop is the durable long-run moat. Repeat customers are worth 22× more than average customers. A competitor entering at 18 months post-launch can replicate the product in 6–12 months — but starts with zero subscriber outcome data, zero formulation iterations informed by real-world use, and zero correlations between adherence patterns and health outcomes. The data moat begins compounding from first subscriber, and every month of market lead expands it irreversibly.^[7]

The hidden CDMO threat: a contract manufacturer that also operates its own supplement brand has structural access to every formula it manufactures. Selecting a B2B-only CDMO with documented full IP ownership transfer is a non-negotiable structural requirement, not a preference. No NDA fully eliminates the conflict of interest in a dual-mode manufacturer.^[7]

Actionable Recommendations

1. Launch in NZ now, before the Pharmac funding decision expands the competitive field.
   The current NZD $7–$15M TAM is too small to attract Blackmores or Swisse. But if Pharmac funds Wegovy under broad BMI criteria, the addressable user base expands from ~62K current Wegovy users toward a far larger pool — up to ~500,000 NZ adults if adoption tracks US rates of ~1 in 8 adults^[8] — and AU incumbents will enter within 12–18 months of that signal. The brand that owns clinical credibility, GP/pharmacist endorsements, and subscriber data by the time the funding decision lands is the default beneficiary of that expansion. The brand that waits until after funding will fight for table scraps against operators with distribution scale. Priority: Critical Supporting pillars: GLP-1 Adoption, Market Sizing, Competitive Landscape, Strategic Risk.
2. Lock full formulation IP ownership and initiate patent prosecution before the first shipment.
   Select a B2B-only CDMO. Require full IP ownership transfer in the manufacturing agreement. Commission a patent search on the proposed GLP-1 companion nutrition formulation combination within the first 60 days of product development. Patent prosecution must begin within months 1–12 — not later. This is not a legal nicety; it is the primary barrier preventing a competitor with distribution scale from copying the product once the category proves commercially viable. Priority: Critical Supporting pillars: Strategic Risk.
3. Pursue rfynd and Well Revolution as referral channel partners, not competitors.
   Both platforms prescribe GLP-1 medications and sell zero companion supplements. They serve the exact private-pay patient population that represents the highest-value SAM. A co-promotion arrangement (prescriber information pack, pharmacist recommendation card, patient onboarding material) converts these platforms from untapped inventory to structured referral channels at near-zero CAC. This must be established before Hims & Hers brings its US supplement cross-sell model to its Eucalyptus AU infrastructure. Priority: High Supporting pillars: Competitive Landscape, Channel Economics, Consumer Behavior.
4. Default acquisition offer: annual subscription at a meaningful discount, not monthly.
   Annual plans reduce churn by 51% versus monthly billing — the single highest-leverage retention move available without any change to product or content. Offer it at acquisition, not as an upsell after the customer has already selected monthly. Pair with a pause option to capture the cycling behavior of GLP-1 users who periodically reduce or stop medication. Implement Recharge + Klaviyo dunning automation before launch — 22% of supplement brand churn is involuntary payment failure, and every recovered churner is free revenue. Priority: High Supporting pillars: Channel Economics, Consumer Behavior.
5. Product architecture: protein + micronutrient + GI support in a single SKU, at NZD/AUD $80–$120/month.
   Consumer research (n=multiple surveys) converges tightly: 75% prioritize vitamin/nutrient fortification, 74% prioritize high protein, 73% prioritize gut health support. Only ~1% of global products currently combine high protein and high fiber claims. This is the formulation gap and the market position simultaneously. Pricing above NZD $120/month requires clinical differentiation (branded ingredients, clinical citations) that a launch product cannot yet claim. Pricing below $80 sends a quality signal inconsistent with the clinical positioning and compresses the LTV:CAC math below viability at ~AUD $150 blended CAC. Priority: High Supporting pillars: Consumer Behavior, Clinical Evidence, Channel Economics.
6. Initiate Canada NPN application immediately — 12–18 month lead time is the gating constraint.
   Canada has ~3 million active GLP-1 users, and generic semaglutide (the first G7 approval) is expected to reduce costs by 65%, creating a demand-side expansion comparable to what PBS listing will do in AU. Health Canada's 180-day review target means the application window opens 12–18 months before any commercial launch date. If Canadian launch is year 2 or 3 on the expansion roadmap, the NPN application should be filed before NZ launch. No other expansion market has a mandatory pre-market gate with this lead time (NZ and UK do not; AU requires ARTG listing but it is faster). Priority: High Supporting pillars: Regulatory Landscape.
7. Obtain TGA ARTG listing pre-AU launch and MHRA borderline opinion pre-UK launch — treat them as launch prerequisites, not post-launch compliance.
   AU launch without ARTG listing is unlawful supply; TGA issued 70+ infringement notices totalling AU$1 million against 19 entities in 8 months in 2024. UK launch with unapproved health claims is a criminal offence since October 2024. Both gates are manageable with forward planning (4–8 weeks for ARTG; MHRA covers up to 4 products per borderline opinion). Commission both before any AU or UK launch date is set. Priority: Medium Supporting pillars: Regulatory Landscape.
8. Build a GP/pharmacist clinical education infrastructure in the first 12 months.
   81% of all 2023 new semaglutide starts in AU were GP-initiated; 400,000+ GLP-1 users in AU are dispensed prescriptions through community pharmacy.^[8] Dietitians NZ and Dietitians Australia have both called for systematic nutritional support alongside GLP-1 prescriptions without endorsing specific brands — the clinical professional community is primed for a credentialed manufacturer to fill this gap. A clinical advisory board, GP information packs, and pharmacist CPD materials (NZ pharmacist CPD hours required per year) cost a fraction of equivalent paid media spend and deliver a trust signal that no amount of TikTok spend replicates. Priority: Medium Supporting pillars: GLP-1 Adoption, Consumer Behavior, Competitive Landscape, Strategic Risk.
9. Sequence expansion in three waves: AU first (TTMRA), then UAE + South Korea, then Singapore + Hong Kong + Japan.
   The expansion-markets screening (41 markets scored, 6 deep-dived; with substantive coverage of 8 notable rejections including the UK, US, China mainland, Canada, Germany, India, Poland, and Brazil) recommends a specific three-wave sequence. Wave 1 (0–6 mo post-NZ): Australia via TTMRA — lowest-friction launch on the planet, but vacancy=2 means the window closes in months not years (JSHealth signalling, Hims·Eucalyptus integrating, Naturecan already in market). Wave 2 (6–12 mo): UAE + South Korea — UAE on the back of NZ-UAE CEPA (98.5% duty-free, August 2025) and Foundayo's April 2026 launch creating a brand-new patient cohort; South Korea capturing the 400,000+ pure-out-of-pocket GLP-1 cohort before KGC's GLPro line locks the position. Wave 3 (12–18 mo): Singapore + Hong Kong + Japan — Singapore as the SEA bridgehead (HSA framework cleanest in Asia, English labels sufficient), Hong Kong as premium standalone + China bridge via Tmall Global cross-border ecommerce, Japan as the highest-trust NZ-provenance market with documented uncontested off-label cosmetic-GLP-1 cohort. UK and Canada are not in the near-term portfolio: vacancy=1 (UK already crowded with Numan/Voy/Juniper/Therapie; Canada US-spillover-dominated); Canada NPN's 6–12-month lead time means application still starts pre-NZ-launch if year-3 launch is the goal. UK entry is viable only under specific conditions (acquisition of a UK-origin GLP-1 companion brand, telehealth B2B2C partnership, or super-narrow niche) detailed in Section 9 of the Expansion Markets analysis. Aggregate envelope across all six markets: ~USD $400–750K over 18–24 months, with each wave largely self-funding from the prior wave's revenue. Priority: High Supporting pillars: Expansion Markets, Regulatory Landscape, Strategic Risk, Competitive Landscape.

Gaps and Limitations

1. No AU/NZ supplement attach rate data exists. Every market size model in this research uses US proxies (Acosta Group: ~30% of GLP-1 users purchase protein products) with discount assumptions applied for AU/NZ. The NZD $7–$15M current TAM and AUD $132–$288M figures are directionally reliable but could be off by a factor of 2 in either direction depending on actual AU/NZ attach behavior. Commissioning primary research with 500–1,000 AU/NZ GLP-1 users on supplement purchase behavior would reduce this uncertainty from the single largest input variable in the model to a quantified number.^[3][2]

2. No GLP-1-specific supplementation RCT has ever been conducted. Both PMC12685510 and PMC12693348, the two sources most favorable to the supplementation thesis, state this explicitly. The entire clinical case for companion supplements is extrapolated from bariatric surgery protocols, general obesity weight-loss research, and mechanistic rationale. The bariatric analogy is the strongest available framework but is explicitly imperfect — bariatric bypass causes malabsorption in addition to reduced intake; GLP-1 causes reduced intake only, meaning bariatric supplement protocols may be overcalibrated. Any clinician who reviews the clinical marketing copy will push back on this gap. A 90-day observational study of 100–150 GLP-1 users supplementing versus non-supplementing would materially strengthen the evidence base and provide the clinical credibility that no existing competitor has established.^[1]

3. No AU/NZ DTC company has ever disclosed CAC or LTV publicly. The AUD ~$150 blended CAC benchmark is inferred from Hims & Hers operational disclosures and US/AU Meta platform data, not from direct AU supplement DTC disclosure. Real acquisition cost in the NZ market (smaller audience, less mature social ecosystem) may be materially higher. Any financial model building to breakeven should stress-test at AUD $200–$250 blended CAC before committing to channel mix assumptions.^[4]

4. The Pharmac funding timeline is the largest demand-side unknown. Pharmac's own position is "we cannot say when or if any medicine will be funded." Full eligible population funding would exceed NZD $3 billion/year at current prices — more than Pharmac's entire annual medicine budget in many years. The research models a step-change in NZ market size contingent on funding, but the timing range (late 2026 optimistically; 2028+ realistically) and the criteria scope (BMI ≥27 with CVD? BMI ≥30 with comorbidity? Narrower?) remain open. The NZ market model at NZD $7–$15M is valid for the current private-pay scenario; the funded scenario requires re-modelling once criteria are confirmed.^[3]

5. B12 supplementation evidence is weaker than commonly marketed. The cross-sectional dietary intake study in non-T2D GLP-1 users (n=69) found B12 intake was adequate in that cohort. The serum B12 decline documented in T2D populations is confounded by metformin co-use and potential assay interference from semaglutide itself. B12 is defensible in a multi-formulation context with metformin co-users but should not be highlighted as a standalone primary deficiency claim for the non-T2D weight-loss cohort without additional supporting data.^[1]

Pillar Cross-Reference

Home